network member

New York University Cancer Institute

160 East 34th Street, 8th Floor, New York, NY 10016 - USA
New York University Cancer Institute

About Network Member

The mission of the Laura and Isaac Perlmutter Cancer Center is to discover the origins of human cancer and to use that knowledge to eradicate the personal and societal burden of cancer in its community, the nation, and the world. Using a team approach, the Perlmutter Cancer Center brings together experts from a variety of disciplines to create collaborative research endeavors and clinical care teams. It offers the full continuum of personalized care, from prevention through diagnosis, treatment, and post-treatment support. As a translational cancer center, its scientists and other researchers share a goal of understanding how cancer develops at the molecular level, and how they can harness that knowledge to reduce the risk of cancer and to treat the disease. The Perlmutter Cancer Center is accelerating the pace of its research and clinical care for all types of human cancer. Website: Laura and Isaac Perlmutter Cancer Center
Currently Enrolling

HCRN-BRE20-468

A Phase II Study of Ribociclib And Endocrine Treatment of Physician’s Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study)
Cancer areas:Breast
Fred & Pamela Buffett Cancer Center
New York University Cancer Institute
Orlando Health Cancer Institute
Parkview Research Center
Penn State Cancer Institute
Providence Cancer Institute
Rutgers Cancer Institute of New Jersey
The Ohio State University
Tufts Medical Center
University of Alabama at Birmingham Comprehensive Cancer Center
University of Arizona Cancer Center
University of Illinois Cancer Center
University of Iowa Holden Comprehensive Cancer Center
University of Michigan Health-West
University of Michigan Rogel Cancer Center
University of Virginia Cancer Center
University of Wisconsin Carbone Cancer Center
Enrollment Closed

BTCRC-BRE16-042

A Phase II Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients: Big Ten Cancer Research Consortium BTCRC-BRE16-042
Cancer areas:Breast
Fred & Pamela Buffett Cancer Center
Michigan State University
New York University Cancer Institute
Rutgers Cancer Institute of New Jersey
University of Wisconsin Carbone Cancer Center
Enrollment Closed

BTCRC-GI20-457

A Phase II study of Atezolizumab and Bevacizumab in Child-Pugh B7 Hepatocellular Carcinoma (The AB7 Trial) Big Ten Cancer Research Consortium BTCRC-GI20-457
Cancer areas:Liver and Bile Duct
DHR Health
Fred & Pamela Buffett Cancer Center
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
New York University Cancer Institute
Rutgers Cancer Institute of New Jersey
University of Illinois Cancer Center
University of Wisconsin Carbone Cancer Center
Enrollment Closed

BTCRC-LUN19-396

A Phase II Study of Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select IIIA [T3N1, T4N0-1] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)
Cancer areas:Lung
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
New York University Cancer Institute
Penn State Cancer Institute
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Rutgers Cancer Institute of New Jersey
Summit Health Cancer Center
The Ohio State University
University of Virginia Cancer Center
University of Wisconsin Carbone Cancer Center